Literature DB >> 16005029

Modulatory action of metabotropic glutamate receptor (mGluR) 5 on mGluR1 function in striatal cholinergic interneurons.

P Bonsi1, D Cuomo, C De Persis, D Centonze, G Bernardi, P Calabresi, A Pisani.   

Abstract

Within basal ganglia, group I metabotropic glutamate receptor subtypes (mGluR1 and 5) frequently co-localize in the same neuron. However, little is known about how these receptors functionally interact. We addressed this issue by means of electrophysiological recordings of striatal cholinergic interneurons, a neuronal subtype that co-express both group I mGluRs. The group I non-selective agonist 3,5-DHPG induced a membrane depolarization/inward current that was prevented by co-application of LY 367385, a selective mGluR1 antagonist, and SIB 1757 or MPEP, blockers of mGluR5 subtype. The reversal potential for the response to 3,5-DHPG was close to the equilibrium potential for potassium channels. Repeated bath or focal applications of 3,5-DHPG induced a progressive decline in the amplitude of the membrane depolarization, suggesting that group I mGluRs undergo receptor desensitization. Interestingly, in the presence of the mGluR5 blocker, SIB 1757, this event was not observed, whereas it occurred in LY 367385. PKC blockers chelerythrine and calphostin C mimicked the inhibitory effect of SIB 1757. In a subset of interneurons, in MPEP or SIB 1757, 3,5-DHPG induced a 0.5-1 Hz oscillatory response, that was prevented by L-type Ca2+ channel blockers, and by the tyrosine kinase inhibitors genistein and lavendustin. Together, these data suggest that mGluR5 modulates mGluR1 activity to shape cell excitability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005029     DOI: 10.1016/j.neuropharm.2005.05.012

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  27 in total

1.  Increased Metabotropic Glutamate Receptor 5 Signaling Underlies Obsessive-Compulsive Disorder-like Behavioral and Striatal Circuit Abnormalities in Mice.

Authors:  Kristen K Ade; Yehong Wan; Harold C Hamann; Justin K O'Hare; Weirui Guo; Anna Quian; Sunil Kumar; Srishti Bhagat; Ramona M Rodriguiz; William C Wetsel; P Jeffrey Conn; Kafui Dzirasa; Kimberly M Huber; Nicole Calakos
Journal:  Biol Psychiatry       Date:  2016-05-13       Impact factor: 13.382

2.  Co-localization of caldesmon and calponin with cortical afferents, metabotropic glutamate and neurotrophic receptors in the lateral and central nuclei of the amygdala.

Authors:  Khristofor Agassandian; Martin D Cassell
Journal:  Brain Res       Date:  2008-06-11       Impact factor: 3.252

3.  Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.

Authors:  Kathy Sengmany; Shane D Hellyer; Sabine Albold; Taide Wang; P Jeffrey Conn; Lauren T May; Arthur Christopoulos; Katie Leach; Karen J Gregory
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

4.  Activation of group I metabotropic glutamate receptors modulates locomotor-related motoneuron output in mice.

Authors:  Noboru Iwagaki; Gareth B Miles
Journal:  J Neurophysiol       Date:  2011-02-23       Impact factor: 2.714

5.  Cholinergic Neurons of the Medial Septum Are Crucial for Sensorimotor Gating.

Authors:  Junghee Jin; Jia Cheng; Ko-Woon Lee; Bushra Amreen; Kathryn A McCabe; Clark Pitcher; Thomas Liebmann; Paul Greengard; Marc Flajolet
Journal:  J Neurosci       Date:  2019-04-26       Impact factor: 6.167

6.  Interaction of DHPG-LTD and synaptic-LTD at senescent CA3-CA1 hippocampal synapses.

Authors:  Ashok Kumar; Thomas C Foster
Journal:  Hippocampus       Date:  2014-01-14       Impact factor: 3.899

Review 7.  The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells.

Authors:  Yonatan Ganor; Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-03-02       Impact factor: 3.575

Review 8.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

9.  Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin.

Authors:  G Martella; P Platania; D Vita; G Sciamanna; D Cuomo; A Tassone; A Tscherter; T Kitada; P Bonsi; J Shen; A Pisani
Journal:  Exp Neurol       Date:  2008-11-21       Impact factor: 5.330

Review 10.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.